pharma · Mantle Cell Lymphoma · Colon cancer
Fondazione Telethon ETS
Fondazione Telethon ETS is a pharma organization headquartered in EU. Primary therapeutic focus areas include Mantle Cell Lymphoma, Colon cancer, colorectal cancer, NSCLC non-small cell lung cancer, Follicular lymphoma.
Approved · small molecule · obesity
Esomeprazole is an approved proton pump inhibitor (PPI) marketed under the brand APO-ESOMEPRAZOLE by multiple sponsors including Alphapharm Pty Ltd, Apotex Pty Ltd, Arrow Pharma Pty Ltd, AstraZeneca Pty Ltd, and Generic Health Pty Ltd. The drug is classified in the Alimentary tract and metabolism therapeutic class (A02
Internal code E S G I S
Esomeprazole is an approved proton pump inhibitor (PPI) marketed under the brand APO-ESOMEPRAZOLE by multiple sponsors including Alphapharm Pty Ltd, Apotex Pty Ltd, Arrow Pharma Pty Ltd, AstraZeneca Pty Ltd, and Generic Health Pty Ltd. The drug is classified in the Alimentary tract and metabolism therapeutic class (A02). In this program, Fondazione Telethon ETS is investigating esomeprazole's role in obesity management, specifically examining its effect on the structural integrity of endoscopic sleeve gastroplasty (ESG), a minimally invasive bariatric procedure. The program is currently active and approved for this investigational indication. The latest disclosed milestone is a single-centre, open-label, randomized, controlled pilot clinical trial evaluating proton pump inhibitors' effects on ESG outcomes. Esomeprazole has established regulatory approval in Australia (TGA, first listed 2002–2010) and the European Union (EMA authorization 25 February 2025, MAH: Haleon Ireland Dungarvan Limited). The mechanism of action and specific molecular target for the obesity indication remain undisclosed. This represents a repurposing strategy for an established PPI in a novel bariatric intervention context.
Obesity remains a significant unmet medical need with limited pharmacological options beyond GLP-1 receptor agonists and combination therapies. Endoscopic sleeve gastroplasty is an emerging minimally invasive alternative to traditional bariatric surgery, offering reduced morbidity compared to surgical approaches. The structural integrity of ESG devices is critical to long-term efficacy and safety; acid-related complications could compromise device durability and clinical outcomes. By investigating whether proton pump inhibition protects ESG structural integrity, this program addresses a potential mechanism of device failure and may expand the therapeutic utility of PPIs beyond acid suppression into bariatric support. The competitive landscape includes established GLP-1 agonists (semaglutide, tirzepatide/Mounjaro) and combination therapies (cagrilintide + semaglutide, Mysimba, Wegovy). Esomeprazole's repurposing as an adjunctive obesity therapy could differentiate it in the bariatric space if efficacy is demonstrated. The patient population includes individuals undergoing ESG who are at risk of device-related complications. Commercial significance depends on whether ESG adoption accelerates and whether adjunctive PPI therapy becomes standard of care in this indication.
Drug Class: Proton pump inhibitor (PPI); Alimentary tract and metabolism (ATC A02).
Modality: Small molecule.
Mechanism of Action: Not yet disclosed for the obesity indication; standard PPI mechanism involves irreversible inhibition of the H+/K+-ATPase pump in gastric parietal cells, reducing gastric acid secretion.
Molecular Target: Not yet disclosed for this program.
Route of Administration: Not yet disclosed.
Brand Name: APO-ESOMEPRAZOLE.
Related Therapies: Other PPIs (pantoprazole, omeprazole); GLP-1 agonists (semaglutide, tirzepatide) for obesity; bariatric interventions (endoscopic sleeve gastroplasty, gastric bypass, gastric banding).
First Approval: Australia (TGA) first listed 2002–2010; European Union (EMA) authorized 25 February 2025.
Patent Status: Not yet disclosed.
Also known as: obesity, obesity disease
A disorder involving an excessive amount of body fat.
ClinicalTrials.gov lists 50 registered studies for Obesity (Disorder) (AACT aggregate).
Phase breakdown: NA (46), PHASE4 (3), PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0011122), Orphanet — obesity disorder, NCT03412149, NCT06787001, NCT06852391, NCT06881485, NCT06911918, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
TGA approval (Australia)
Esomeprazole first listed in the Australian Register of Therapeutic Goods.
EMA authorization
Haleon Ireland Dungarvan Limited received EMA authorization for esomeprazole (EMEA/H/C/002618).
Obesity indication pilot trial (active)
Single-centre, open-label, randomized, controlled pilot clinical trial evaluating effect of proton pump inhibitors on endoscopic sleeve gastroplasty structural integrity (NCT 2024-517679-18-00).
The obesity therapeutic landscape is dominated by GLP-1 receptor agonists and combination therapies. Semaglutide (approved, United Therapeutics Europe Ltd and NovoThirteen) and tirzepatide/Mounjaro (approved, The George Institute) represent the current standard of care for pharmacological weight management. Wegovy (semaglutide 0.25–2.4 mg, NovoThirteen) and cagrilintide + semaglutide combinations (NovoThirteen) offer additional options. Mysimba (naltrexone/bupropion, Disc Medicine) represents an older combination approach. Esomeprazole's proposed role as an adjunctive therapy protecting endoscopic sleeve gastroplasty structural integrity is distinct from these weight-loss-focused competitors; it targets device durability rather than appetite suppression. The competitive advantage, if validated, would be complementary rather than direct—used alongside bariatric procedures rather than as monotherapy. Pantoprazole (APO-PANTOPRAZOLE, Alphapharm Pty Ltd) is a related PPI competitor in the acid suppression space but not specifically positioned for obesity. Success of this esomeprazole program depends on ESG adoption rates and clinical evidence that PPI co-therapy improves device longevity and patient outcomes, differentiating it from established weight-loss medications.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| APO-PANTOPRAZOLE | Alphapharm Pty Ltd | — | approved |
| Mounjaro 5 mg solution for injection in pre-filled pen, Mounjaro 2.5 mg solution for injection in pre-filled pen | The George Institute | small_molecule | approved |
| Semaglutide | United Therapeutics Europe Ltd | small_molecule | approved |
| RIMEGEPANT , Capsaicin | Disc Medicine | small_molecule | approved |
| Simvastatin | Hospital Authority, Hong Kong | small_molecule | approved |
| Candesartan and Hydrochlorothiazide | Takeda | small_molecule | approved |
| Pioglitazone | Takeda | small_molecule | approved |
| Mysimba 8 mg/90 mg prolonged-release tablets | Disc Medicine | small_molecule | approved |
| Semaglutide B 3.0 mg/ml PDS290 | Disc Medicine | small_molecule | approved |
| Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen | NovoThirteen | small_molecule | approved |
| cagrilintide, Placebo + Placebo, semaglutide, cagrilintide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, cagrilintide semaglutide, semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide, cagrilintide | NovoThirteen | small_molecule | approved |
| Sulfato de Magnesio Altan 150 mg/ml solución inyectable y para perfusión EFG, LIDOCAINE HYDROCHLORIDE, Dexdor 100 micrograms/ml concentrate for solution for infusion, KETOLAR 50 mg/ml solución inyectable. | The George Institute | small_molecule | approved |
| SIBUTRAMINE | — | Monoamine transporter inhibitor | Approved |
| SETMELANOTIDE ACETATE | — | Melanocortin receptor 4 agonist | Approved |
| SETMELANOTIDE | — | Melanocortin receptor 4 agonist | Approved |
| RIMONABANT | — | Cannabinoid CB1 receptor antagonist | Approved |
| PHENTERMINE HYDROCHLORIDE | — | Norepinephrine transporter releasing agent | Approved |
| PHENTERMINE | — | Norepinephrine transporter releasing agent | Approved |
| PHENDIMETRAZINE TARTRATE | — | Norepinephrine transporter inhibitor | Approved |
| ORLISTAT | — | Pancreatic lipase inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Australia (TGA): Esomeprazole approved; first listed 2002–2010. Multiple sponsors hold PBS codes (10295W, 10330Q, 10331R, 10343J, 11687D, 11692J, 12275C, 12283L, 12287Q, 12290W). Sponsors include Alphapharm Pty Ltd, Apotex Pty Ltd, Arrow Pharma Pty Ltd, AstraZeneca Pty Ltd, and Generic Health Pty Ltd. Evidence available at https://www.tga.gov.au/resources/artg?keywords=esomeprazole.
European Union (EMA): Esomeprazole approved. Marketing Authorization Holder: Haleon Ireland Dungarvan Limited. Authorization date: 25 February 2025. EMA product number: EMEA/H/C/002618. Evidence available at https://www.ema.europa.eu/en/medicines/human/EPAR/nexium-control.
FDA (United States): Regulatory status not yet disclosed.
PMDA (Japan): Regulatory status not yet disclosed.
NMPA (China): Regulatory status not yet disclosed.
Obesity Indication: The program is active and approved for investigation; specific regulatory pathway for the ESG-protective indication not yet disclosed.
In this program, esomeprazole is being investigated for its potential to protect the structural integrity of endoscopic sleeve gastroplasty (ESG), a minimally invasive bariatric procedure for obesity management.
Esomeprazole is approved as a proton pump inhibitor for acid-related disorders in Australia (TGA, first listed 2002–2010) and the European Union (EMA, authorized 25 February 2025). The obesity indication is currently under investigation in a pilot clinical trial and is not yet approved for this use.
Esomeprazole is a proton pump inhibitor that reduces gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase pump in gastric parietal cells. Its specific mechanism in protecting ESG structural integrity has not yet been disclosed.
Fondazione Telethon ETS is the sponsor of the esomeprazole obesity program investigating its effect on endoscopic sleeve gastroplasty.
The program is active and approved for investigation. A single-centre, open-label, randomized, controlled pilot clinical trial is underway (NCT 2024-517679-18-00).
A single-centre, open-label, randomized, controlled pilot clinical trial (NCT 2024-517679-18-00) is evaluating the effect of proton pump inhibitors on the structural integrity of endoscopic sleeve gastroplasty.
Multiple manufacturers hold approvals: Alphapharm Pty Ltd, Apotex Pty Ltd, Arrow Pharma Pty Ltd, AstraZeneca Pty Ltd, and Generic Health Pty Ltd in Australia; Haleon Ireland Dungarvan Limited in the European Union.
The brand name is APO-ESOMEPRAZOLE, marketed by multiple sponsors including Alphapharm Pty Ltd and Apotex Pty Ltd.
Esomeprazole was first listed in the Australian Register of Therapeutic Goods between 2002 and 2010. It received EMA authorization on 25 February 2025.
Endoscopic sleeve gastroplasty is a minimally invasive bariatric procedure used to treat obesity. The esomeprazole program is investigating whether proton pump inhibition protects the structural integrity of ESG devices.
Esomeprazole is a proton pump inhibitor classified in the Alimentary tract and metabolism therapeutic class (ATC A02).
Direct obesity competitors include GLP-1 agonists (semaglutide, tirzepatide/Mounjaro), combination therapies (cagrilintide + semaglutide, Mysimba, Wegovy), and bariatric procedures. Esomeprazole would be adjunctive rather than a direct replacement.
Results from the pilot clinical trial (NCT 2024-517679-18-00) have not yet been reported.
The specific mechanism of action for the obesity indication has not yet been disclosed. Standard PPI mechanism involves acid suppression, but the protective effect on ESG structural integrity requires further investigation.
FDA regulatory status for esomeprazole in the obesity indication has not yet been disclosed.
The route of administration for esomeprazole in the obesity program has not yet been disclosed.
Expected next milestones include completion and publication of the pilot trial, potential initiation of larger randomized controlled trials, and regulatory guidance on the obesity indication pathway. Specific dates have not yet been disclosed.
ESOMEPRAZOLE, ESOMEPRAZOLE → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Fondazione Telethon ETS is pursuing a repurposing strategy for an established, off-patent PPI into a novel bariatric indication. This approach leverages existing safety and manufacturing infrastructure while addressing a potential unmet need in ESG durability. Success could establish a new standard of care for ESG patients and extend the commercial lifecycle of esomeprazole in obesity management.
Competitive Implications: Esomeprazole would not compete directly with GLP-1 agonists but rather complement them or serve as adjunctive therapy in bariatric procedures. If efficacy is demonstrated, it could become part of a multimodal obesity treatment algorithm. The lack of patent protection on esomeprazole itself may limit commercial upside but reduces regulatory and IP barriers to adoption.
Clinical Catalysts: Publication of pilot trial results will be critical. Positive data on ESG structural integrity preservation could trigger larger phase 2/3 trials and potential label expansion. Adoption of ESG as a preferred bariatric intervention would increase the addressable patient population.
Expected Milestones: Completion and publication of the single-centre pilot trial; potential initiation of multi-centre randomized controlled trials; regulatory guidance on obesity indication pathway; potential label expansion in Australia and EU.
Regulatory Pathway: The obesity indication may follow a novel indication pathway given esomeprazole's established safety profile in acid suppression. Regulatory approval for the ESG-protective indication would likely require demonstration of clinical benefit (reduced device failure, improved weight loss durability, or improved safety) in controlled trials.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.